Samtidig administration af TNF- antagonister og abatacept er blevet forbundet med en forhøjet risiko for infektioner inklusiv alvorlige infektioner sammenlignet med behandling med TNF- antagonister alene, uden forøget klinisk fordel.
Concurrent administration of TNF-antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF-antagonists alone, without increased clinical benefit.